CDK9 and cancer: We report here that elevated pretreatment levels of caspase-8 and cyclin-dependent kinase 9 (CDK9) are associated with significantly improved relapse-free, distant metastasis-free and cancer-specific survival, while, in contrast, higher levels of phosphorylated CDK9 predict an increased risk of recurrence and distant metastases, and inferior cancer-specific survival.